Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Research Report 2024(Status and Outlook)
Report Overview
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
This report provides a deep insight into the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market in any manner.
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Market Segmentation (by Type)
Therapeutics
Diagnostics
Market Segmentation (by Application)
Hospital
Clinic
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
This report provides a deep insight into the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market in any manner.
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Market Segmentation (by Type)
Therapeutics
Diagnostics
Market Segmentation (by Application)
Hospital
Clinic
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
- Overview of the regional outlook of the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
1.2 Key Market Segments
1.2.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Type
1.2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Manufacturers (2019-2024)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Sites, Area Served, Product Type
3.6 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Competitive Situation and Trends
3.6.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS INDUSTRY CHAIN ANALYSIS
4.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)
6.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type (2019-2024)
6.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Price by Type (2019-2024)
7 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Sales by Application (2019-2024)
7.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
8 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY REGION
8.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region
8.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region
8.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Siemens Healthcare
9.1.1 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.1.2 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.1.4 Siemens Healthcare Business Overview
9.1.5 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
9.1.6 Siemens Healthcare Recent Developments
9.2 Celerion
9.2.1 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.2.2 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.2.4 Celerion Business Overview
9.2.5 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
9.2.6 Celerion Recent Developments
9.3 ZyVersa Therapeutics, Inc.
9.3.1 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.3.2 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.3.4 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
9.3.5 ZyVersa Therapeutics, Inc. Business Overview
9.3.6 ZyVersa Therapeutics, Inc. Recent Developments
9.4 Cisbio
9.4.1 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.4.2 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.4.4 Cisbio Business Overview
9.4.5 Cisbio Recent Developments
9.5 Regeneron Pharmaceuticals, Inc.
9.5.1 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.5.2 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.5.4 Regeneron Pharmaceuticals, Inc. Business Overview
9.5.5 Regeneron Pharmaceuticals, Inc. Recent Developments
9.6 BioPredictive
9.6.1 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.6.2 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.6.4 BioPredictive Business Overview
9.6.5 BioPredictive Recent Developments
9.7 Echosens
9.7.1 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.7.2 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.7.4 Echosens Business Overview
9.7.5 Echosens Recent Developments
9.8 Genfit
9.8.1 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.8.2 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.8.4 Genfit Business Overview
9.8.5 Genfit Recent Developments
9.9 Enterome
9.9.1 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.9.2 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.9.4 Enterome Business Overview
9.9.5 Enterome Recent Developments
9.10 NGM Biopharmaceuticals
9.10.1 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.10.2 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.10.4 NGM Biopharmaceuticals Business Overview
9.10.5 NGM Biopharmaceuticals Recent Developments
10 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST BY REGION
10.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast
10.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country
10.2.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Region
10.2.4 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type (2025-2030)
11.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type (2025-2030)
11.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Application (2025-2030)
11.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) Forecast by Application
11.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
1.2 Key Market Segments
1.2.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Type
1.2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Manufacturers (2019-2024)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Sites, Area Served, Product Type
3.6 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Competitive Situation and Trends
3.6.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS INDUSTRY CHAIN ANALYSIS
4.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)
6.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type (2019-2024)
6.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Price by Type (2019-2024)
7 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Sales by Application (2019-2024)
7.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
8 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY REGION
8.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region
8.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region
8.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Siemens Healthcare
9.1.1 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.1.2 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.1.4 Siemens Healthcare Business Overview
9.1.5 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
9.1.6 Siemens Healthcare Recent Developments
9.2 Celerion
9.2.1 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.2.2 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.2.4 Celerion Business Overview
9.2.5 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
9.2.6 Celerion Recent Developments
9.3 ZyVersa Therapeutics, Inc.
9.3.1 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.3.2 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.3.4 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
9.3.5 ZyVersa Therapeutics, Inc. Business Overview
9.3.6 ZyVersa Therapeutics, Inc. Recent Developments
9.4 Cisbio
9.4.1 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.4.2 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.4.4 Cisbio Business Overview
9.4.5 Cisbio Recent Developments
9.5 Regeneron Pharmaceuticals, Inc.
9.5.1 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.5.2 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.5.4 Regeneron Pharmaceuticals, Inc. Business Overview
9.5.5 Regeneron Pharmaceuticals, Inc. Recent Developments
9.6 BioPredictive
9.6.1 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.6.2 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.6.4 BioPredictive Business Overview
9.6.5 BioPredictive Recent Developments
9.7 Echosens
9.7.1 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.7.2 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.7.4 Echosens Business Overview
9.7.5 Echosens Recent Developments
9.8 Genfit
9.8.1 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.8.2 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.8.4 Genfit Business Overview
9.8.5 Genfit Recent Developments
9.9 Enterome
9.9.1 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.9.2 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.9.4 Enterome Business Overview
9.9.5 Enterome Recent Developments
9.10 NGM Biopharmaceuticals
9.10.1 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
9.10.2 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
9.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Market Performance
9.10.4 NGM Biopharmaceuticals Business Overview
9.10.5 NGM Biopharmaceuticals Recent Developments
10 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST BY REGION
10.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast
10.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country
10.2.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Region
10.2.4 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type (2025-2030)
11.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type (2025-2030)
11.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast by Application (2025-2030)
11.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) Forecast by Application
11.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Comparison by Region (M USD)
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2022)
Table 10. Global Market Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Sites and Area Served
Table 12. Manufacturers Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Type
Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges
Table 22. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Type (K Units)
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (M USD)
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Share by Type (2019-2024)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) by Application
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)
Table 33. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2019-2024)
Table 35. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)
Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 43. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 44. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 45. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Siemens Healthcare Business Overview
Table 47. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
Table 48. Siemens Healthcare Recent Developments
Table 49. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 50. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 51. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Celerion Business Overview
Table 53. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
Table 54. Celerion Recent Developments
Table 55. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 56. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 57. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
Table 59. ZyVersa Therapeutics, Inc. Business Overview
Table 60. ZyVersa Therapeutics, Inc. Recent Developments
Table 61. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 62. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 63. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Cisbio Business Overview
Table 65. Cisbio Recent Developments
Table 66. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 67. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 68. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Regeneron Pharmaceuticals, Inc. Business Overview
Table 70. Regeneron Pharmaceuticals, Inc. Recent Developments
Table 71. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 72. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 73. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. BioPredictive Business Overview
Table 75. BioPredictive Recent Developments
Table 76. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 77. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 78. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Echosens Business Overview
Table 80. Echosens Recent Developments
Table 81. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 82. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 83. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Genfit Business Overview
Table 85. Genfit Recent Developments
Table 86. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 87. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 88. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Enterome Business Overview
Table 90. Enterome Recent Developments
Table 91. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 92. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 93. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. NGM Biopharmaceuticals Business Overview
Table 95. NGM Biopharmaceuticals Recent Developments
Table 96. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Comparison by Region (M USD)
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2022)
Table 10. Global Market Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Sites and Area Served
Table 12. Manufacturers Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Type
Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges
Table 22. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Type (K Units)
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (M USD)
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Share by Type (2019-2024)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) by Application
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)
Table 33. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2019-2024)
Table 35. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)
Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)
Table 43. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 44. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 45. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Siemens Healthcare Business Overview
Table 47. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
Table 48. Siemens Healthcare Recent Developments
Table 49. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 50. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 51. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Celerion Business Overview
Table 53. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
Table 54. Celerion Recent Developments
Table 55. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 56. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 57. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics SWOT Analysis
Table 59. ZyVersa Therapeutics, Inc. Business Overview
Table 60. ZyVersa Therapeutics, Inc. Recent Developments
Table 61. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 62. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 63. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Cisbio Business Overview
Table 65. Cisbio Recent Developments
Table 66. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 67. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 68. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Regeneron Pharmaceuticals, Inc. Business Overview
Table 70. Regeneron Pharmaceuticals, Inc. Recent Developments
Table 71. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 72. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 73. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. BioPredictive Business Overview
Table 75. BioPredictive Recent Developments
Table 76. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 77. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 78. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Echosens Business Overview
Table 80. Echosens Recent Developments
Table 81. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 82. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 83. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Genfit Business Overview
Table 85. Genfit Recent Developments
Table 86. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 87. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 88. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Enterome Business Overview
Table 90. Enterome Recent Developments
Table 91. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Basic Information
Table 92. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Overview
Table 93. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. NGM Biopharmaceuticals Business Overview
Table 95. NGM Biopharmaceuticals Recent Developments
Table 96. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD), 2019-2030
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) (2019-2030)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (M USD)
Figure 11. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Share by Manufacturers in 2023
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Share by Manufacturers in 2023
Figure 13. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type
Figure 18. Sales Market Share of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type (2019-2024)
Figure 19. Sales Market Share of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type in 2023
Figure 20. Market Size Share of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application
Figure 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Application in 2023
Figure 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2019-2024)
Figure 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application in 2023
Figure 28. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 32. U.S. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 37. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 44. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 50. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 51. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD), 2019-2030
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (M USD) (2019-2030)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (M USD)
Figure 11. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Share by Manufacturers in 2023
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Share by Manufacturers in 2023
Figure 13. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type
Figure 18. Sales Market Share of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type (2019-2024)
Figure 19. Sales Market Share of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type in 2023
Figure 20. Market Size Share of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application
Figure 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Application in 2023
Figure 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2019-2024)
Figure 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application in 2023
Figure 28. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 32. U.S. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 37. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 44. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 50. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 51. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share Forecast by Application (2025-2030)
